ENBI Stock Overview
Entheon Biomedical Corp. operates as a biotechnology research and development company.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Entheon Biomedical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.35 |
| 52 Week Low | CA$0.05 |
| Beta | 1.5 |
| 1 Month Change | 81.82% |
| 3 Month Change | 100.00% |
| 1 Year Change | -20.00% |
| 3 Year Change | -95.74% |
| 5 Year Change | n/a |
| Change since IPO | -96.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENBI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 33.3% | -1.1% | 0.7% |
| 1Y | -20.0% | -38.2% | 5.5% |
Return vs Industry: ENBI exceeded the Canadian Biotechs industry which returned -37.9% over the past year.
Return vs Market: ENBI underperformed the Canadian Market which returned 6.1% over the past year.
Price Volatility
| ENBI volatility | |
|---|---|
| ENBI Average Weekly Movement | 110.9% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ENBI's share price has been volatile over the past 3 months.
Volatility Over Time: ENBI's weekly volatility has increased from 72% to 111% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | Timothy Ko | www.entheonbiomedical.com |
Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp. Fundamentals Summary
| ENBI fundamental statistics | |
|---|---|
| Market cap | CA$2.04m |
| Earnings (TTM) | -CA$300.00k |
| Revenue (TTM) | CA$250.32k |
7.1x
P/S Ratio-5.9x
P/E RatioIs ENBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENBI income statement (TTM) | |
|---|---|
| Revenue | CA$250.32k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$250.32k |
| Other Expenses | CA$550.32k |
| Earnings | -CA$300.00k |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 100.00% |
| Net Profit Margin | -119.85% |
| Debt/Equity Ratio | 0% |
How did ENBI perform over the long term?
See historical performance and comparison